Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25907902 | 0.82 | POLB (0.60) | POLBCTDSP1MEN1KMT2AMAPT | |
| SCHEMBL25908024 | 0.80 | MMP9 (0.53) | CTSKMMP9CTSS | |
| SCHEMBL28553978 | 0.79 | POLB (0.57) | POLBCTDSP1MEN1KMT2AMAPT | |
| SCHEMBL28970083 | 0.78 | CNR1 (0.45) | CTSKCASRCTSS | |
| SCHEMBL4331889 | 0.78 | CA12 (0.49) | MEN1KMT2ACTSKL3MBTL1MAPT | |
| SCHEMBL25695969 | 0.76 | NAALAD2 (0.41) | CTSKCTSS | |
| SCHEMBL28022209 | 0.76 | RIPK1 (0.57) | CTSKCTSS | |
| SCHEMBL7405567 | 0.75 | CTSK (0.43) | MEN1KMT2ACTSKMAPTALDH1A1 | |
| SCHEMBL12203593 | 0.75 | CTSK (0.62) | MEN1KMT2ACTSKMAPTALDH1A1 | |
| SCHEMBL6346030 | 0.75 | CTSK (0.62) | MEN1KMT2ACTSKMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912644-B2 | Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate | CELGENE CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234914-A1 | PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE | CELGENE CORPORATION | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234914-A1 | PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE | UMPS, DHPS, NT5C3B | POLB 27/4885CTDSP1 57/4885MEN1 4232/4885 |
| US-11912644-B2 | Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate | UMPS, DHPS, NT5C3B | POLB 27/4885CTDSP1 57/4885MEN1 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.